Abstract Details

Title Long-term Efficacy of Zonisamide on Parkinsonism in Dementia with Lewy Bodies: A Post-hoc Analysis of Phase 3 Trial

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-012

Objective Zonisamide is available as an agent for parkinsonism in both Parkinson’s disease and dementia with Lewy bodies (DLB) in Japan. The objective of this presentation is to characterize the long-term efficacy of zonisamide on motor symptoms in DLB.

Background Not applicable

Design/Methods Of the patients participated in the phase 3 trial consisting of 12-week, randomized double-blind and subsequent 40-week, open-label phases, those who were assigned to zonisamide groups (25 or 50 mg/day) in the double-blind phase and received zonisamide at least once were included in this analysis. Because the flexible dose (25 or 50 mg/day) of zonisamide was allowed in the open-label phase, both zonisamide groups were summed as an analysis population. UPDRS part 3 was employed for the evaluation of motor dysfunction. Focusing on the individual motor symptoms such as tremor (UPDRS part 3 item number; #20, #21), rigidity (#22), bradykinesia (#23 to #26, #31) and gait disturbance/postural instability (#29, #30), the respective summed scores were analyzed.

Results Summary statistics showed that tremor, rigidity and bradykinesia were improved with time. At around Week 28-32, the maximal effect on rigidity and bradykinesia were observed (Change [%change] from baseline: rigidity, -1.4 [-20.6%]; bradykinesia, -2.5 [-18.2%]). In addition, Tremor known as the symptom which is non-notable one in DLB was remarkably improved at around the final evaluation time point (-1.6 [-51.8%]).

Conclusions Long-term use of zonisamide was found to improve individual symptoms such as tremor, rigidity and bradykinesia besides overall parkinsonism in DLB patients. Other data will be shown on the day.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Kazuko Hasegawa, MD (Dept Neurology, Sagamihara Natl Hospital)	Dr. Hasegawa has nothing to disclose.
	No disclosure on file
Shunji Toya	Shunji Toya has received personal compensation for serving as an employee of Sumitomo Dainippon Pharma Co., Ltd..
	No disclosure on file

��ɫ��

��ɫ��